IL10 and cancer: In stage I/II melanoma patients, RNA levels of IL-10 and IFN-γ, which code for proteins that can induce DCs to express the immunosuppressive enzyme IDO, were discovered to be higher in patients with either cancer-positive sentinel lymph nodes (SLNs) or residual primary tumor, compared to patients with negative SLNs [78].